-BioStrand now offers a Customizable Application Programming
Interface (API) with its new software offering, LENSai API,
featuring the ability to integrate sizable databases and electronic
health records with large language models.
-BioStrand’s novel software is rapidly and directly integrable
into pharmaceutical, healthcare, and technology companies to
enhance drug discovery capabilities.
-This proprietary software provides the integration of
electronic health records, enhancing AI-driven drug discovery and
development for industry professionals.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or
“IPA” or the “Company”), a leader in AI-driven biotherapeutic
research and technology, today announces the commercial release of
LENSai API, hereafter referred to as the ‘software’, by its
subsidiary, BioStrand. This advanced AI-driven software solution is
available immediately.
More details on this new offering will be unveiled today at 2:00
pm ET, with an additional presentation, live demonstration, and
interview at 6:30 pm ET, all taking place at the InterSystems
Global Summit 2024. This premier event, which attracts over 1,200
industry leaders from more than 28 countries, showcases the latest
innovations in the field.
IPA, the #1 ranked contract research organization by Roots
Analysis2, serves 19 of the top 20 global pharmaceutical companies
and over 600 clients in the pharmaceutical and biotech industries.
Leveraging feedback from these long-term relationships, the
development of this AI-driven software is in direct response to
meeting ongoing industry pain points and needs. These new software
capabilities demonstrate innovation by combining BioStrand’s
patented LENSai technology with electronic health records through a
customizable interface to enable unprecedented research and drug
discovery capabilities.
Dr. Dirk Van Hyfte is leading the launch of this exciting
integration, enabling industry professionals to quickly and easily
access and merge patient data, company research data, and extensive
life science databases. Through this new release, corporations will
be able to analyze major datasets related to generating novel and
potentially safer and more effective drugs, as the BioStrand team
continues to develop a full LENSai data management platform,
expected to be released in Q1/Q2 2025.
Dr. Dirk Van Hyfte stated, "We have received significant
interest in our new technology from large healthcare,
pharmaceutical, and technology companies. They are keen on
accessing our unique capabilities through an integration that
enables them to benefit directly from BioStrand's novel
applications for data analysis and cutting-edge drug discovery. The
Company regards the commercial launch of this pioneering software
as its most significant AI breakthrough to date, poised to
significantly enhance global drug discovery and development
processes. By integrating BioStrand’s software with electronic
health records, and adding BioStrand’s application programming
interface, we have surpassed internal timelines and milestones,
supporting the rapid commercialization of these high-demand
capabilities."
These new commercial capabilities will significantly enhance
BioStrand’s ability to commercialize:
- Partnerships with Large Companies: Major pharmaceutical,
technology, and healthcare companies will be able to rapidly
leverage BioStrand’s new software capabilities through partnerships
that may include upfront payments, clinical milestones and
commercial royalties.
- Subscription Model: BioStrand is offering a subscription
service that enables a wide range of technology, healthcare, and
pharmaceutical companies to access BioStrand’s unique capabilities
using integration of the software into their existing platforms,
with a strong probability of enhancing their drug discovery and
development programs.
In light of the upcoming presentation at the InterSystem’s
Global Summit 2024, Dr. Dirk Van Hyfte has requested that the live
podcast, media events, and interviews be recorded and made
available to the public whenever possible. We also encourage
everyone who can attend the live demonstration at the summit to
join and support this exciting public commercial launch. You can
register: InterSystems Global Summit 2024 Registration.
1www.strategyand.pwc.com/de/en/industries/pharma-life-science/re-inventing-pharma-with-artificial-intelligence.html
2ROOTS 2022, Antibody Discovery Services and Platforms Market
(4th Edition), 2021-2035; pp.118
About ImmunoPrecise Antibodies Ltd.
The IPA Family is a biotherapeutic research and technology group
that leverages systems biology, multi-omics modelling and complex
artificial intelligence systems to support its proprietary
technologies in bioplatform-based antibody discovery. Services
include highly specialized, full-continuum therapeutic biologics
discovery, development, and out-licensing to support its business
partners in their quest to discover and develop novel biologics
against the most challenging targets. ImmunoPrecise Antibodies Ltd.
has several subsidiaries in North America and Europe including
entities such as Talem Therapeutics LLC, BioStrand BV,
ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies
(Europe) B.V. (collectively, the “IPA Family”).
For further information, visit www.ipatherapeutics.com.
Forward Looking Information
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information contained in this news
release includes, but is not limited to, statements relating to the
expected outcome on the market, the life sciences, drug discovery
and development, integration and / or success of LENSai, LLMs, RAG,
or HYFT technologies, including their benefits, and statements
relating to IPA’s expected increased revenue streams and financial
growth. In respect of the forward-looking information contained
herein, IPA has provided such statements and information in
reliance on certain assumptions that management believed to be
reasonable at the time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, the risk that the integration of IPA’s LENSai platform
with its HYFT technology may not have the expected results, risks
that the expected healthcare benefits including lowering
development timeliness, and costs and that development of targeted
treatments with higher efficacy and lower side effects will not be
achieved, risks that the benefits to drug discovery, protein-based
therapeutics, and synthetic biology won't be achieved, in addition
actual results could differ materially from those currently
anticipated due to a number of factors and risks, as discussed in
the Company’s Annual Information Form dated July 10, 2023 (which
may be viewed on the Company’s profile at www.sedar.com), and the
Company’s Form 40-F, dated July 10, 2023 (which may be viewed on
the Company’s profile at www.sec.gov). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. Accordingly, readers should not
place undue reliance on forward-looking information contained in
this news release. The forward-looking statements contained in this
news release are made as of the date of this release and,
accordingly, are subject to change after such date. The Company
does not assume any obligation to update or revise any
forward-looking statements, whether written or oral, that may be
made from time to time by us or on our behalf, except as required
by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240610639834/en/
Investor contact: investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
過去 株価チャート
から 5 2024 まで 6 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
過去 株価チャート
から 6 2023 まで 6 2024